Quest Diagnostics (DGX) PT Raised to $250 at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts DGX Hot Sheet
Price: $238.93 +0.76%
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
UBS analyst Kevin Caliendo raised the price target on Quest Diagnostics (NYSE: DGX) to $250.00 (from $245.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Abbott Labs (ABT) PT Lowered to $125 at BTIG
- Calumet Specialty Products Partners (CLMT) PT Raised to $57 at Goldman Sachs
- AT&T (T) PT Lowered to $27 at Goldman Sachs, 'higher costs working capital & costs weigh on outlook'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
